A PHASE IB CLINICAL STUDY WITH 18F-FDG-PET RESPONSE EVALUATION OF THE COMBINATION OF TEMSIROLIMUS (T) AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN BREAST, ENDOMETRIAL AND OVARIAN CANCER